Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 529

1.

Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses.

Botton T, Talevich E, Mishra VK, Zhang T, Shain AH, Berquet C, Gagnon A, Judson RL, Ballotti R, Ribas A, Herlyn M, Rocchi S, Brown KM, Hayward NK, Yeh I, Bastian BC.

Cell Rep. 2019 Oct 15;29(3):573-588.e7. doi: 10.1016/j.celrep.2019.09.009.

2.

Genetic characterization of Carnivore Parvoviruses in Spanish wildlife reveals domestic dog and cat-related sequences.

Calatayud O, Esperón F, Velarde R, Oleaga Á, Llaneza L, Ribas A, Negre N, de la Torre A, Rodríguez A, Millán J.

Transbound Emerg Dis. 2019 Oct 3. doi: 10.1111/tbed.13378. [Epub ahead of print]

PMID:
31581349
3.

Tumour-intrinsic resistance to immune checkpoint blockade.

Kalbasi A, Ribas A.

Nat Rev Immunol. 2019 Sep 30. doi: 10.1038/s41577-019-0218-4. [Epub ahead of print] Review.

PMID:
31570880
4.

Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.

Zhu Y, Smith DJ, Zhou Y, Li YR, Yu J, Lee D, Wang YC, Di Biase S, Wang X, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu CG, Ribas A, Kohn DB, Witte ON, Yang L.

Cell Stem Cell. 2019 Oct 3;25(4):542-557.e9. doi: 10.1016/j.stem.2019.08.004. Epub 2019 Sep 5.

PMID:
31495780
5.

Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood.

Peng S, Zaretsky JM, Ng AHC, Chour W, Bethune MT, Choi J, Hsu A, Holman E, Ding X, Guo K, Kim J, Xu AM, Heath JE, Noh WJ, Zhou J, Su Y, Lu Y, McLaughlin J, Cheng D, Witte ON, Baltimore D, Ribas A, Heath JR.

Cell Rep. 2019 Sep 3;28(10):2728-2738.e7. doi: 10.1016/j.celrep.2019.07.106.

6.

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.

Lewis KD, Larkin J, Ribas A, Flaherty KT, McArthur GA, Ascierto PA, Dréno B, Yan Y, Wongchenko M, McKenna E, Zhu Q, Mun Y, Hauschild A.

Br J Cancer. 2019 Oct;121(7):522-528. doi: 10.1038/s41416-019-0546-y. Epub 2019 Aug 16.

PMID:
31417188
7.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalá M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ.

Ann Oncol. 2019 Aug 13. pii: mdz221. doi: 10.1093/annonc/mdz221. [Epub ahead of print] No abstract available.

PMID:
31406976
8.

Biochar application and summer temperatures reduce N2O and enhance CH4 emissions in a Mediterranean agroecosystem: Role of biologically-induced anoxic microsites.

Ribas A, Mattana S, Llurba R, Debouk H, Sebastià MT, Domene X.

Sci Total Environ. 2019 Oct 1;685:1075-1086. doi: 10.1016/j.scitotenv.2019.06.277. Epub 2019 Jun 19.

PMID:
31390698
9.

Sound Localization Test in Presence of Noise (Sound Localization Test) in Adults without Hearing Alteration.

Almeida GVM, Ribas A, Calleros J.

Int Arch Otorhinolaryngol. 2019 Jul;23(3):e276-e280. doi: 10.1055/s-0038-1676657. Epub 2019 Mar 1.

10.

Comparing Individuals through the Speech Recognition Test Applied to Regional Live Voice and Recorded Speeches from Paraná State in Five Brazilian Counties.

Mafra NV, Ribas A, Moretti C, Zeigelboim BS, Fonseca VR, Borburema RM.

Int Arch Otorhinolaryngol. 2019 Jul;23(3):e256-e261. doi: 10.1055/s-0038-1668127. Epub 2018 Oct 24.

11.

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long GV.

Lancet Oncol. 2019 Sep;20(9):1239-1251. doi: 10.1016/S1470-2045(19)30388-2. Epub 2019 Jul 22.

PMID:
31345627
12.

Health Innovation Laboratories: towards strong Primary Health Care (PHC)in the Federal District of Brasilia.

Tasca R, Ventura ILS, Borges V, Leles FAG, Gomes RM, Ribas AN, Carvalho WM, Jimenez JMS.

Cien Saude Colet. 2019 Jun 27;24(6):2021-2030. doi: 10.1590/1413-81232018246.08672019. Portuguese, English.

13.

Characterisation of gastrointestinal helminths and their impact in commercial small-scale chicken flocks in the Mekong Delta of Vietnam.

Van NTB, Cuong NV, Yen NTP, Nhi NTH, Kiet BT, Hoang NV, Hien VB, Thwaites G, Carrique-Mas JJ, Ribas A.

Trop Anim Health Prod. 2019 Jul 2. doi: 10.1007/s11250-019-01982-3. [Epub ahead of print]

PMID:
31267344
14.

Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.

Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH Jr, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghori R, Moreno BH, Ibrahim N, Hamid O.

Nat Med. 2019 Aug;25(8):1319. doi: 10.1038/s41591-019-0535-y.

PMID:
31267021
15.

Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib.

Lewis K, Hauschild A, Larkin J, Ribas A, Flaherty KT, McArthur GA, Dréno B, McKenna E, Zhu Q, Mun Y, Ascierto PA.

Eur J Cancer. 2019 Jul;116:45-55. doi: 10.1016/j.ejca.2019.05.002. Epub 2019 Jun 4.

PMID:
31173962
16.

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.

Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH Jr, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghori R, Moreno BH, Ibrahim N, Hamid O.

Nat Med. 2019 Jun;25(6):936-940. doi: 10.1038/s41591-019-0476-5. Epub 2019 Jun 6. Erratum in: Nat Med. 2019 Aug;25(8):1319.

PMID:
31171879
17.

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.

Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, Couture F, Mookerjee B, Ghori R, Ibrahim N, Moreno BH, Ribas A.

Nat Med. 2019 Jun;25(6):941-946. doi: 10.1038/s41591-019-0448-9. Epub 2019 Jun 6.

PMID:
31171878
18.

Phenotypic heterogeneity and evolution of melanoma cells associated with targeted therapy resistance.

Su Y, Bintz M, Yang Y, Robert L, Ng AHC, Liu V, Ribas A, Heath JR, Wei W.

PLoS Comput Biol. 2019 Jun 5;15(6):e1007034. doi: 10.1371/journal.pcbi.1007034. eCollection 2019 Jun.

19.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV.

N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4.

PMID:
31166680
20.

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response.

Sharma A, Subudhi SK, Blando J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P.

Clin Cancer Res. 2019 Jun 1;25(11):3469-3470. doi: 10.1158/1078-0432.CCR-19-0402. No abstract available.

21.

Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer.

Hu-Lieskovan S, Lisberg A, Zaretsky JM, Grogan TR, Rizvi H, Wells DK, Carroll J, Cummings A, Madrigal J, Jones B, Gukasyan J, Shintaku IP, Slamon D, Dubinett S, Goldman JW, Elashoff D, Hellmann MD, Ribas A, Garon EB.

Clin Cancer Res. 2019 Aug 15;25(16):5061-5068. doi: 10.1158/1078-0432.CCR-18-4275. Epub 2019 May 21.

PMID:
31113840
22.

UCLA PTSD reaction index for DSM-5 (PTSD-RI-5): a psychometric study of adolescents sampled from communities in eleven countries.

Doric A, Stevanovic D, Stupar D, Vostanis P, Atilola O, Moreira P, Dodig-Curkovic K, Franic T, Davidovic V, Avicenna M, Noor M, Nussbaum L, Thabet A, Ubalde D, Petrov P, Deljkovic A, Antonio ML, Ribas A, Oliveira J, Knez R.

Eur J Psychotraumatol. 2019 May 7;10(1):1605282. doi: 10.1080/20008198.2019.1605282. eCollection 2019.

23.

Decarboxylation mechanisms of C4 photosynthesis in Saccharum spp.: increased PEPCK activity under water-limiting conditions.

Cacefo V, Ribas AF, Zilliani RR, Neris DM, Domingues DS, Moro AL, Vieira LGE.

BMC Plant Biol. 2019 Apr 16;19(1):144. doi: 10.1186/s12870-019-1745-7.

24.

Brazilian Scale of Hearing and Language Development: Normality Curve for Infants and Children from 0 to 24 Months Old with Normal Hearing.

Moretti C, Ribas A, Guarinello AC, Rosa M, Riesemberg R, Vassoler T, Sypczuk G, Martins J.

Int Arch Otorhinolaryngol. 2019 Apr;23(2):131-136. doi: 10.1055/s-0038-1675189. Epub 2019 Feb 15.

25.

Interleukin 32 expression in human melanoma.

Paz H, Tsoi J, Kalbasi A, Grasso CS, McBride WH, Schaue D, Butterfield LH, Maurer DM, Ribas A, Graeber TG, Economou JS.

J Transl Med. 2019 Apr 5;17(1):113. doi: 10.1186/s12967-019-1862-y.

26.

Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.

Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A.

Eur J Cancer. 2019 May;112:29-31. doi: 10.1016/j.ejca.2019.01.015. Epub 2019 Mar 21. No abstract available.

PMID:
30903870
27.

Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition.

Chat V, Ferguson R, Simpson D, Kazlow E, Lax R, Moran U, Pavlick A, Frederick D, Boland G, Sullivan R, Ribas A, Flaherty K, Osman I, Weber J, Kirchhoff T.

Cancer Immunol Immunother. 2019 Jun;68(6):897-905. doi: 10.1007/s00262-019-02318-8. Epub 2019 Mar 12.

PMID:
30863922
28.

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma.

Yan Y, Wongchenko MJ, Robert C, Larkin J, Ascierto PA, Dréno B, Maio M, Garbe C, Chapman PB, Sosman JA, Shi Z, Koeppen H, Hsu JJ, Chang I, Caro I, Rooney I, McArthur GA, Ribas A.

Clin Cancer Res. 2019 Jun 1;25(11):3239-3246. doi: 10.1158/1078-0432.CCR-18-0720. Epub 2019 Mar 1.

PMID:
30824584
29.

TGF-β1 polymorphism in American tegumentary leishmaniasis in a Southern Brazilian population.

Shehadeh FVB, Santos RRD, Silva LADD, Silva Júnior WVD, Ribas-Silva R, Ribas AD, Silveira TGV, Borelli SD, Aristides SMA.

Rev Soc Bras Med Trop. 2019 Feb 21;52:e20170415. doi: 10.1590/0037-8682-0415-2017.

30.

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, Dronca R, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Zhao Q, Jensen E, Ahsan S, Ibrahim N, Ribas A.

Ann Oncol. 2019 Apr 1;30(4):582-588. doi: 10.1093/annonc/mdz011.

31.

T cell antigen discovery via trogocytosis.

Li G, Bethune MT, Wong S, Joglekar AV, Leonard MT, Wang JK, Kim JT, Cheng D, Peng S, Zaretsky JM, Su Y, Luo Y, Heath JR, Ribas A, Witte ON, Baltimore D.

Nat Methods. 2019 Feb;16(2):183-190. doi: 10.1038/s41592-018-0305-7. Epub 2019 Jan 28.

32.

T cell antigen discovery via signaling and antigen-presenting bifunctional receptors.

Joglekar AV, Leonard MT, Jeppson JD, Swift M, Li G, Wong S, Peng S, Zaretsky JM, Heath JR, Ribas A, Bethune MT, Baltimore D.

Nat Methods. 2019 Feb;16(2):191-198. doi: 10.1038/s41592-018-0304-8. Epub 2019 Jan 28.

33.

Hormones and Auditory Perception: Study of Dichotic Listening in Women during the Menstrual Cycle.

Carneiro CDS, Almeida AAF, Ribas A, Kluk-De Kort K, Lima DO, Araújo AMGD, Ferreira DAH, Martins ML, Freitas TMMWC, de Rosa MRD.

Int Arch Otorhinolaryngol. 2019 Jan;23(1):70-76. doi: 10.1055/s-0038-1626701. Epub 2018 May 9.

34.

A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.

Nowicki TS, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, Kaplan-Lefko P, Cabrera P, Tran J, Pang J, Macabali M, Garcilazo IP, Carretero IB, Kalbasi A, Cochran AJ, Grasso CS, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh A, Ribas A.

Clin Cancer Res. 2019 Apr 1;25(7):2096-2108. doi: 10.1158/1078-0432.CCR-18-3496. Epub 2018 Dec 20.

PMID:
30573690
35.

Detection of Neospora caninum (Toxoplasmatidae) in wild small mammals from Thailand.

Japa O, Morand S, Karnchanabanthoeng A, Chaisiri K, Ribas A.

Folia Parasitol (Praha). 2018 Nov 27;65. pii: 2018.018. doi: 10.14411/fp.2018.018.

36.

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.

Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC.

Clin Cancer Res. 2018 Dec 1;24(23):6098. doi: 10.1158/1078-0432.CCR-18-3340. No abstract available.

PMID:
30510087
37.

Parasitic infections in relation to practices and knowledge in a rural village in Northern Thailand with emphasis on fish-borne trematode infection.

Chaisiri K, Jollivet C, Della Rossa P, Sanguankiat S, Wattanakulpanich D, Lajaunie C, Binot A, Tanita M, Rattanapikul S, Sutdan D, Morand S, Ribas A.

Epidemiol Infect. 2018 Nov 15:1-12. doi: 10.1017/S0950268818002996. [Epub ahead of print]

38.

Holobiont suture zones: Parasite evidence across the European house mouse hybrid zone.

Goüy de Bellocq J, Wasimuddin, Ribas A, Bryja J, Piálek J, Baird SJE.

Mol Ecol. 2018 Dec;27(24):5214-5227. doi: 10.1111/mec.14938. Epub 2018 Dec 10.

PMID:
30427096
39.

IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.

Puig-Saus C, Parisi G, Garcia-Diaz A, Krystofinski PE, Sandoval S, Zhang R, Champhekar AS, McCabe J, Cheung-Lau GC, Truong NA, Vega-Crespo A, Komenan MDS, Pang J, Macabali MH, Saco JD, Goodwin JL, Bolon B, Seet CS, Montel-Hagen A, Crooks GM, Hollis RP, Campo-Fernandez B, Bischof D, Cornetta K, Gschweng EH, Adelson C, Nguyen A, Yang L, Witte ON, Baltimore D, Comin-Anduix B, Kohn DB, Wang X, Cabrera P, Kaplan-Lefko PJ, Berent-Maoz B, Ribas A.

Clin Cancer Res. 2019 Feb 1;25(3):1000-1011. doi: 10.1158/1078-0432.CCR-18-0963. Epub 2018 Nov 8.

PMID:
30409823
40.

High diversity of hemotropic mycoplasmas in Iberian wild carnivores.

Millán J, Velarde R, Delicado V, Negre N, Ribas A, Oleaga Á, Llaneza L, Esperón F.

Comp Immunol Microbiol Infect Dis. 2018 Oct;60:11-16. doi: 10.1016/j.cimid.2018.09.007. Epub 2018 Sep 27.

PMID:
30396424
41.

Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules.

Bethune MT, Li XH, Yu J, McLaughlin J, Cheng D, Mathis C, Moreno BH, Woods K, Knights AJ, Garcia-Diaz A, Wong S, Hu-Lieskovan S, Puig-Saus C, Cebon J, Ribas A, Yang L, Witte ON, Baltimore D.

Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10702-E10711. doi: 10.1073/pnas.1810653115. Epub 2018 Oct 22.

42.

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.

Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, Zhang C, Lunceford JK, Joe A, Cheng J, Webber AL, Ibrahim N, Plimack ER, Ott PA, Seiwert TY, Ribas A, McClanahan TK, Tomassini JE, Loboda A, Kaufman D.

Science. 2018 Oct 12;362(6411). pii: eaar3593. doi: 10.1126/science.aar3593. Erratum in: Science. 2019 Mar 1;363(6430):.

43.

Spermatological characteristics of the family Glypthelminthidae (Digenea, Plagiorchioidea) inferred from the ultrastructural study of Glypthelmins staffordi Tubangui, 1928.

Miquel J, Poonlaphdecha S, Ribas A.

Tissue Cell. 2018 Oct;54:114-119. doi: 10.1016/j.tice.2018.08.013. Epub 2018 Aug 29.

PMID:
30309500
44.

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.

Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, Arance AS, Brown E, Hoeller C, Mortier L, Schachter J, Long J, Ebbinghaus S, Ibrahim N, Butler M.

Br J Cancer. 2018 Sep;119(6):670-674. doi: 10.1038/s41416-018-0207-6. Epub 2018 Sep 11.

45.

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.

Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS.

Cancer Discov. 2018 Oct;8(10):1250-1257. doi: 10.1158/2159-8290.CD-18-0280. Epub 2018 Aug 28.

46.

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.

Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A.

Eur J Cancer. 2018 Sep;101:236-243. doi: 10.1016/j.ejca.2018.06.034. Epub 2018 Aug 7.

47.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV.

Cell. 2018 Aug 9;174(4):1031-1032. doi: 10.1016/j.cell.2018.07.035. No abstract available.

48.

Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.

Hauschild A, Larkin J, Ribas A, Dréno B, Flaherty KT, Ascierto PA, Lewis KD, McKenna E, Zhu Q, Mun Y, McArthur GA.

JAMA Oncol. 2018 Oct 1;4(10):1382-1388. doi: 10.1001/jamaoncol.2018.2668.

49.

OCCASIONAL DIGESTIVE HEMORRHAGE IN CHILDREN DUE TO STRONGYLOIDIASIS: IMPORTANCE OF PARASITOLOGIC TESTING.

Brandelero E, Dambrós BP, Gonçalves EMDN, Castilho VLP, Ribas AM, Gaio ME.

Rev Paul Pediatr. 2019 Jan-Mar;37(1):121-125. doi: 10.1590/1984-0462/;2019;37;1;00013. Epub 2018 Jul 26. Portuguese, English.

50.

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers.

Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P.

Clin Cancer Res. 2019 Feb 15;25(4):1233-1238. doi: 10.1158/1078-0432.CCR-18-0762. Epub 2018 Jul 27.

PMID:
30054281

Supplemental Content

Support Center